GlassScriptPhysician profile
Samuel M Puleo
NPI 1073521217
$552.19
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $74.42 · 2021: $92.18 · 2022: $76.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $142.61 | 2019 | |
| Pacira Therapeutics, INC. | $109.49 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $80.78 | 2019-2022 | |
| Pfizer INC. | $47.41 | 2019 | |
| Fidia Pharma USA INC. | $38.41 | 2019-2020 | |
| Stryker Corporation | $33.68 | 2021 | |
| Horizon Therapeutics Plc | $26.82 | 2022 | |
| Avanos Medical | $18.37 | 2022 | |
| Zyla Life Sciences, INC. | $16.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.19 | 2019 | |
| Depuy Synthes Sales INC. | $13.91 | 2022 | |
| Orthofix Medical, INC. | $8.28 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Puleo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.